Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma.
作者信息
Gustine Joshua N, Branagan Andrew R, Cirstea Diana D, Rexha Farah, Han Ryan, Yee Andrew J, Maus Marcela V, Frigault Matthew J, Raje Noopur S
机构信息
Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA.
出版信息
Blood Adv. 2025 Jun 24;9(12):3026-3030. doi: 10.1182/bloodadvances.2025015981.
Abstract
摘要
相似文献
1
Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma.克隆性造血对多发性骨髓瘤中BCMA嵌合抗原受体T细胞（CAR-T）临床结局的影响。
Blood Adv. 2025 Jun 24;9(12):3026-3030. doi: 10.1182/bloodadvances.2025015981.
2
Bicistronic CAR-T Cell against BCMA and CD229 effectively controls myeloma even when BCMA expression is limited.针对BCMA和CD229的双顺反子嵌合抗原受体T细胞即使在BCMA表达受限的情况下也能有效控制骨髓瘤。
Cancer Immunol Res. 2025 Jun 27. doi: 10.1158/2326-6066.CIR-24-1313.
3
Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma.病例报告：抗BCMA/GPRC5D双特异性CAR-T细胞疗法治疗多发性骨髓瘤中多次CAR-T细胞扩增总结
Front Immunol. 2025 Jun 6;16:1607778. doi: 10.3389/fimmu.2025.1607778. eCollection 2025.
4
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.在既往接受过靶向BCMA治疗的复发/难治性多发性骨髓瘤患者中，替雷利珠单抗的疗效：来自美国多发性骨髓瘤免疫治疗联盟的一项多中心研究。
Blood Cancer J. 2025 Jun 25;15(1):111. doi: 10.1038/s41408-025-01314-9.
5
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis.抗 BCMA CAR-T 细胞疗法治疗多发性骨髓瘤老年患者的安全性和疗效：系统评价和荟萃分析。
J Geriatr Oncol. 2024 Mar;15(2):101628. doi: 10.1016/j.jgo.2023.101628. Epub 2023 Sep 16.
6
Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma.BCMA纳米抗体CAR T细胞疗法治疗复发或难治性浆细胞骨髓瘤的疗效与安全性
Blood Adv. 2025 Sep 23;9(18):4543-4552. doi: 10.1182/bloodadvances.2025016322.
7
Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma.在复发/难治性多发性骨髓瘤中，在进行嵌合抗原受体T细胞（CAR-T）治疗之前，关注塞利尼索用于维持和过渡治疗。
J Clin Med. 2025 Jun 9;14(12):4071. doi: 10.3390/jcm14124071.
8
Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.新型CS1嵌合抗原受体T细胞（CAR-T细胞）和双特异性CS1- BCMA嵌合抗原受体T细胞可有效靶向多发性骨髓瘤。
Biomedicines. 2021 Oct 9;9(10):1422. doi: 10.3390/biomedicines9101422.
9
Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy.克隆性造血与嵌合抗原受体 T 细胞（CART）治疗患者的严重细胞因子释放综合征相关。
Transplant Cell Ther. 2024 Sep;30(9):927.e1-927.e9. doi: 10.1016/j.jtct.2024.06.008. Epub 2024 Jun 11.
10
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.CD38 和 BCMA 双特异性 CAR-T 在复发或难治性多发性骨髓瘤中的高效和安全性。
J Exp Clin Cancer Res. 2022 Jan 3;41(1):2. doi: 10.1186/s13046-021-02214-z.
本文引用的文献
1
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma.促进多发性骨髓瘤患者在接受 BCMA CAR-T 治疗后长期细胞减少症的分子机制。
Blood Adv. 2024 Nov 12;8(21):5479-5492. doi: 10.1182/bloodadvances.2023012522.
2
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.嵌合抗原受体 T 细胞治疗后非复发死亡率的系统评价和荟萃分析。
Nat Med. 2024 Sep;30(9):2667-2678. doi: 10.1038/s41591-024-03084-6. Epub 2024 Jul 8.
3
Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.新诊断多发性骨髓瘤患者的临床结局和克隆性造血演变。
Cancer Res Commun. 2023 Dec 18;3(12):2560-2571. doi: 10.1158/2767-9764.CRC-23-0093.
4
Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant.造血细胞移植治疗多发性骨髓瘤患者的克隆性造血与心血管疾病
JAMA Cardiol. 2024 Jan 1;9(1):16-24. doi: 10.1001/jamacardio.2023.4105.
5
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients.抗CD19嵌合抗原受体T细胞治疗患者中克隆性造血的临床意义及动态变化
Hemasphere. 2023 Oct 3;7(10):e957. doi: 10.1097/HS9.0000000000000957. eCollection 2023 Oct.
6
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.CAR-HEMATOTOX 评分作为接受 BCMA 靶向 CAR-T 治疗复发/难治性多发性骨髓瘤患者毒性和反应的预后模型。
J Hematol Oncol. 2023 Jul 31;16(1):88. doi: 10.1186/s13045-023-01465-x.
7
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。
N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.
8
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.伊达赛利珠单抗或标准方案治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
9
Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment.接受 CD19 靶向 CAR T 细胞治疗的侵袭性淋巴瘤患者中 CHIP 的流行率和变异情况。
Blood Adv. 2022 Mar 22;6(6):1941-1946. doi: 10.1182/bloodadvances.2021005747.
10
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.BCMA CAR T 细胞治疗后复发/难治性多发性骨髓瘤患者的感染并发症。
Blood Adv. 2022 Apr 12;6(7):2045-2054. doi: 10.1182/bloodadvances.2020004079.
Zotero 插件